Bill Rote

Private pilot, instrument student, scientist

[Bill Rote @billrote]

We’re proud to play a role in transforming care in #RareKidneyDisease, and are humbled by the many people who have worked so hard to bring change and innovation to the treatment of #IgAN. #InRareForLife

[Travere Therapeutics @TravereRare]

We are excited to announce that our medicine for the treatment of #IgAnephropathy was granted full approval by the FDA. Today’s approval marks an important milestone in transforming treatment for people living with #RareKidneyDisease. Press release: https://t.co/xzbVWDdpop

[Bill Rote @billrote]

@GVlasuk Hopefully most of this storm stays west of you

[Bill Rote @billrote]

@cholubaz Super cool!

[American Physiological Society @APSPhysiology]

#APSselect mouse study from @AJPRenal finds the nephropathy drug sparsentan improves changes in the kidney associated with inflammatory genes and pathways: https://t.co/TYnWSg5tE5 CC: @AJPRenalEIC

[Travere Therapeutics @TravereRare]

This afternoon in our Q1 earnings update we shared that the FDA has granted Priority Review for our sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S. #InRareForLife
Press release: https://t.co/Dt9AE5fZ2W

[World Congress of Nephrology @ISNWCN]

"SPARSENTAN as First-line Treatment of Incident Patients With IgAN: Preliminary Findings from the SPARTAN Trial" by @toomuchaltitude, et al, was presented at WCN'24. Their work was transformed into a visual abstract by #ISNWCN Social Media Team member @Ironken6

[Travere Therapeutics @TravereRare]

As we wrap up an excellent few days at #SIMD2024, we are delighted to now be a part of the Genetic Metabolic Dieticians International (GMDI) conference where we’ll continue to share our latest research in the rare metabolic disorder classical #homocystinruia (HCU).

[Travere Therapeutics @TravereRare]

At @TheACMG #ACMGMtg24 last week in Toronto, we shared our research in classical #homocystinuria. Dr. Can Ficicioglu presented the latest results of the COMPOSE Study evaluating the effect of pegtibatinase, an investigational therapy for people living with classical HCU.

[Bill Rote @billrote]

@cholubaz That just sounds like VOR voodoo to me

[Chris 🇺🇲 Holub ✈️ @cholubaz]

So far for the Saturday lunch flight fly-in to Catalina AVX we have (2) Cirrus (2) Cherokee 6 (2) Arrow's (2) Cherokee's 1 Mooney, and 1 Bonanza. Could be others but this is what I know of so far. :-) Should be pretty epic! #AvGeek #Pilot #Aviation

[Jula Inrig @InrigJula]

Pleased to share the interim results of the PROTECT study of Sparsentan in IgAN published today in the Lancet in parallel with a late breaking presentation at WCN23

https://t.co/Qrq6vXcMOu

[Chris 🇺🇲 Holub ✈️ @cholubaz]

There should be one of these on every street corner!

[Bill Rote @billrote]

@cholubaz ForeFlight will make this task easier

[Bill Rote @billrote]

@GVlasuk It'll be interesting to see how Max's refusal to help Perez will hurt his popularity, and subsequently his endorsement income.

[Bill Rote @billrote]

@cholubaz Same in my Six. My brain can interpret the analog needle quicker than the tape.

[Bill Rote @billrote]

@cholubaz Looks like a speedy bird. Have you had a chance to see what standard cruise pencils out at yet? From the looks of the paint and the panel, I'd guess right about 200 kts.

[Bill Rote @billrote]

@cholubaz Congratulations! Looking forward to seeing it up close soon.

[Travere Therapeutics @TravereRare]

Today, we announced the presentations of our work in FSGS and IgA nephropathy at #KidneyWk 2022 in Orlando, where we will share two oral presentations and nine posters on our research in rare glomerular diseases. Press release: https://t.co/KsY5FmmC1y #FSGS #IgAN @ASNKidney

[Bill Rote @billrote]

@GVlasuk Hoping that you both came through this safely.

[Bill Rote @billrote]

@RealCarlosSagan None taken at all!